Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 24

1.

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D; LANTERN Investigators.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 5;10:1015-26. doi: 10.2147/COPD.S84436. eCollection 2015.

2.

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. doi: 10.2147/COPD.S62502. eCollection 2014.

3.

Non-inferiority trial between two dry-powder inhalers containing fluticasone/salmeterol in asthmatic patients.

Serra HA, Klapouszko FP, De Salvo MC, Bavasso EC, Rey L, Downey D, Lopez D, Roganovich JM, Rizzo LF.

Drug Res (Stuttg). 2013 Jun;63(6):305-10. doi: 10.1055/s-0033-1341433. Epub 2013 Apr 4.

PMID:
23558603
4.

Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.

MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF.

Thorax. 2013 Aug;68(8):738-45. doi: 10.1136/thoraxjnl-2012-202744. Epub 2013 Mar 28.

PMID:
23539534
5.

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators.

Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

6.

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.

Zuwallack R, De Salvo MC, Kaelin T, Bateman ED, Park CS, Abrahams R, Fakih F, Sachs P, Pudi K, Zhao Y, Wood CC; Combivent Respimat Inhaler Study Group.

Respir Med. 2010 Aug;104(8):1179-88. doi: 10.1016/j.rmed.2010.01.017. Epub 2010 Feb 20.

7.

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators.

Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.

PMID:
19716598
8.

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

Vestbo J, Tan L, Atkinson G, Ward J; UK-500,001 Global Study Team.

Eur Respir J. 2009 May;33(5):1039-44. doi: 10.1183/09031936.00068908. Epub 2009 Feb 12.

9.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

10.
11.

Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae.

van Rensburg D, Fogarty C, De Salvo MC, Rangaraju M, Nusrat R.

J Infect. 2005 Oct;51(3):201-5. Epub 2004 Dec 22.

PMID:
16230216
12.
13.

[Physiopathology, diagnosis and treatment of severe chronic hypoxemia. Role of residential chronic oxygen therapy].

Cáneva JO, Rabec CA, De Salvo MC, Mazzei JA.

Medicina (B Aires). 2001;61(4):453-69. Review. Spanish.

PMID:
11563176
14.

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.

D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J; FOR-INT-03 Study Group.

Chest. 2001 May;119(5):1347-56.

PMID:
11348938
15.

CD4+ T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection.

Pilheu JA, De Salvo MC, Gonzalez J, Rey D, Elias MC, Ruppi MC.

Int J Tuberc Lung Dis. 1997 Oct;1(5):422-6.

PMID:
9441096
16.

[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin].

Pilheu JA, Galati MR, Yunis AS, De Salvo MC, Negroni R, García Fernández JC, Mingolla L, Rubio MC, Masana M, Acevedo C.

Medicina (B Aires). 1989;49(1):43-7. Spanish.

PMID:
2698437
17.

[Tuberculosis and jaundice. Study of 103 cases].

Pilheu JA, De Salvo MC, Barcat JA, Koch OR.

Medicina (B Aires). 1987;47(1):13-9. Spanish. No abstract available.

PMID:
3613966
18.

[Effects of pyrazinamide on the liver in patients with tuberculosis. An ultrastructural study].

Pilheu JA, de Salvo MC, Arias RF, Koch OR.

Medicina (B Aires). 1985;45(1):15-9. Spanish. No abstract available.

PMID:
3880102
19.

[Effect of pyrazinamide on the liver of tuberculosis patients. Electron microscopic study].

Pilheu JA, de Salvo MC, Koch OR, Arias RF.

Bull Int Union Tuberc. 1984 Sep;59(3):145-7. French. No abstract available.

PMID:
6518323
20.

[Relapses in pulmonary tuberculosis. Value of the case history for the selection of the best retreatment regimen].

Pilheu JA, de Salvo MC, Gnecco V, Giannattasio J, Hoffman M.

Medicina (B Aires). 1982;42(4):389-95. Spanish. No abstract available.

PMID:
15171020
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk